INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Florence
Florencia, ItaliaPublicaciones en colaboración con investigadores/as de University of Florence (37)
2024
-
CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)
Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25
-
Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology
PLoS Computational Biology, Vol. 20, Núm. 2
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, Vol. 403, Núm. 10423, pp. 249-260
2023
-
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Blood
-
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
The Lancet, Vol. 401, Núm. 10373, pp. 269-280
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
2022
-
Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Cancer Research, Vol. 82, Núm. 3, pp. 447-457
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
-
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Leukemia, Vol. 36, Núm. 5, pp. 1432-1435
-
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
Blood
-
Reply to Calcifediol Is Not Superior to Cholecalciferol in Improving Vitamin D Status in Postmenopausal Women
Journal of Bone and Mineral Research
2021
-
Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial
Journal of Bone and Mineral Research, Vol. 36, Núm. 10, pp. 1967-1978
-
Imetelstat achieves meaningful and durable transfusion independence in high transfusion–Burden patients with lower-risk myelodysplastic syndromes in a phase II study
Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 48-56
-
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 13, pp. 1426-1436
2020
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
-
Corrigendum: Clinical Features of Headache in Patients With Diagnosis of Definite Vestibular Migraine: The VM-Phenotypes Projects (Frontiers in Neurology, (2018), 9, 10.3389/fneur.2018.00395)
Frontiers in Neurology
-
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk
Journal of Hematology and Oncology, Vol. 13, Núm. 1
-
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
Leukemia Research
-
Preface
Advances in Intelligent Systems and Computing
2019
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973